This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.


Abivax S.A.

Drug Names(s): ABX203, HeberNasvac

Description: ABX203 is a therapeutic vaccine composed of 2 recombinant proteins from HBV, the surface antigen (HBsAg) and the nucleocapsid (core) structure (HBcAg). ABX203 has been designed to induce the production of neutralizing serum antibodies to HBsAg and the induction of strong cellular responses which are weak or undetectable in patients with CHB. ABX203 is formulated as a nasal spray solution and as a solution for sub-cutaneous injection.

Deal Structure: ABIVAX owns distribution rights for ABX203 for more than 80 territories in Asia, Europe and Africa. They were licensed in 2013 from the Center for Genetic Engineering and Biotechnology (CIGB, Havana, Cuba) following the completion of successful Phase I, I/II and III clinical trials run by CIGB in Cuba and Bangladesh.

ABX203 News

Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug